Literature DB >> 10773923

Immunoglobulin therapy in immunohematological disorders.

V P Choudhry1, M Mahapatra, R Kashyap.   

Abstract

Over the last few decades many biological factors have been discovered. Among these immunoglobulins are currently being used for large number of indications. Initially it was used for primary and secondary immunodeficiency states. Subsequently, intravenous immunoglobulins are being used for variety of immunohematological, autoimmune, and immunopathological disorders. In the present communication besides it basic structure, pharmacology and immunoregulation, its use in various hematological disorders is being reviewed. Currently, it is the preferred treatment for conditions such as immune mediated thrombocytopenic purpura, neutropenia, and autoimmune hemolytic anemia.

Entities:  

Mesh:

Year:  1998        PMID: 10773923     DOI: 10.1007/bf02731042

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  40 in total

1.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES.

Authors:  J Stokes; E P Maris; S S Gellis
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

Review 2.  Clinical uses of intravenous immunoglobulin in pregnancy.

Authors:  A L Clark; S A Gall
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

3.  Passive transfer of antibodies to human T-cell lymphotropic virus type III in patients receiving high-dose intravenous immunoglobulin.

Authors:  W B White; R W Ryan; D D Staley; M Ballow
Journal:  JAMA       Date:  1986-05-16       Impact factor: 56.272

4.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

5.  Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin.

Authors:  G Berlin; A Selbing; G Ryden
Journal:  Lancet       Date:  1985-05-18       Impact factor: 79.321

Review 6.  Management of alloimmune neonatal and antenatal thrombocytopenia.

Authors:  M F Reznikoff-Etievant
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

7.  Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study.

Authors:  B Imholz; P Imbach; C Baumgartner; W Berchtold; G Gaedicke; E Gugler; A Hirt; W Hitzig; C Mueller-Eckhardt; H P Wagner
Journal:  Blut       Date:  1988-02

8.  Antenatal treatment of neonatal alloimmune thrombocytopenia.

Authors:  J B Bussel; R L Berkowitz; J G McFarland; L Lynch; U Chitkara
Journal:  N Engl J Med       Date:  1988-11-24       Impact factor: 91.245

Review 9.  Human IgG Fc receptors.

Authors:  C L Anderson
Journal:  Clin Immunol Immunopathol       Date:  1989-11

10.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

Authors:  I M Nilsson; E Berntorp; O Zettervall
Journal:  N Engl J Med       Date:  1988-04-14       Impact factor: 91.245

View more
  1 in total

1.  Abdominal tuberculosis with autoimmune hemolytic anemia.

Authors:  V Gupta; B D Bhatia
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.